Matt Hammond, PhD, MBA

Partner

Matthew Hammond is a Partner at RA Capital Management. Matthew’s primary responsibilities are to work on both public and private investments and to serve as CEO and Board Director of Research Alliance Corp III and Research Alliance Corp IV, and as a Board Director for Ambros Therapeutics. Matthew previously served as a Director on the boards of DTx Pharma, prior to its acquisition by Novartis, Emergence Therapeutics, prior to its acquisition by Eli Lilly, Forge Biologics, prior to its acquisition by Ajinomoto, and Jnana Therapeutics, prior to its acquisition by Otsuka. Matthew also served as the CFO and as a Director of Research Alliance Corp I before its merger with Point Biopharma, which was later acquired by Eli Lilly. Matthew holds a BS in Environmental Health Science from the University of Georgia and both a PhD in Biomedical Science and a MBA with a concentration in Finance from the University of Connecticut.